The Government of Ontario recently announced that they are making significant changes to the availability of high-cost cancer medications. Under its “Funding Accelerated for Specific Treatments” (FAST) program, selected cancer drugs will get more public funding a year faster than is already the case. A three-year pilot initiative, the FAST program aims to fast-track seven to ten high-priority cancer treatments each year. Currently, the following drugs are being funded through this program: Tagrisso ([osimertinib] for lung cancer), Scemblix (for a leukemia variant), Nubeqa (for prostate cancer), Calquence ([acalabrutinib tablets] for lymphoma), Opdivo with Yervoy (for colorectal cancer and for liver cancer). To this we say, hurray. However, in our view, this change highlights a few of the problems that cancer patients have to overcome when they receive a cancer diagnosis in Canada. The first problem is access. In Canada, provinces have a hard task: bri...